金年会

•  During the COVID-19 outbreak, we were the third-party testing unit designated by Huoshenshan Hospital and Leishenshan Hospital, and participated in “Ten-day Battle” community nucleic acid screening.

•  Leaders of Wuhan Municipal People’s Government visited Kindstar Global to investigate nucleic acid testing.

•  Leaders of relevant national departments visited Kindstar Global for inspection and research.

•  Kindstar Global made its international debut and officially joined the American Society of Hematology (ASH).

• A contract was signed for “Kindstar Global – Cleveland” International Digital Pathology Consultation.

• 2019 St. Jude-VIVA-NCMC Pediatric Hematology/Oncology Forum was held in Guangzhou.

•  The Expert Forum on Adult Hematologic Tumor and Pediatric Hematologic Tumor was held in the headquarters. Experts and scholars from all over the country gathered together to discuss the trends and application prospects of precision medicine in hematology. Kindstar Global Eagle Business School officially opened.

• The Huaxi Blood Disease Esoteric Testing Center of Huaxi Kindstar Medical Diagnostics (Sichuan) Co., Ltd., jointly established with West China Hospital, Sichuan University, was formally established.

•  Kindstar Global once again passed the ISO15189 audit.

• The new office building of Kindstar Global headquarters was completed. Tejiankang Health Management Center was formally established. Beijing Hightrust won the CNAS ISO 15189:2012 laboratory accreditation certificate.

• With the approval of the Ministry of Human Resources and Social Security of the People’s Republic of China, Beijing Hightrust established a post-doctoral research station.

• Wuhan Laboratory was awarded the ISO15189 certificate by CNAS. The construction of a new office building covering 27,000 square meters began.

• Signed strategic cooperation with Novartis; completed Series C financing of USD 20 million (Kleiner Perkins KP_CB); cooperated with a total of 3,350 hospitals and signed contracts with 1,685 hospitals.

• Acquired Shanghai Xinpeijing Clinical Molecular Research Center to build a new window for high-end esoteric testing services based in Shanghai; received favorable reviews from Mayo Clinic for the investigation on “Kindstar Global’s Transition Projects in the First Quarter of 2012”; reached formal agreements with 17 of the top 20 hospitals in China.

• Inked a six-year strategic cooperation agreement with Mayo Clinic in the United States to actively introduce high-end tests in various medical specialties; successfully completed Series B financing of USD 11 million (WI Harper Group, and Baird Capital Partners Asia)

• Developed business in Tibet, with its service network covering the whole country.

• Experts from Mayo Clinic in the United States visited the Kindstar Medical Laboratory many times.

• Merged with Beijing Rongheng Global Gene Technology Co., Ltd. to establish Kindstar Global Esoteric Testing Group; introduced high-end esoteric testing services for solid tumor molecular pathology to keep abreast of the latest developments in international oncology.

• Obtained the venture capital of Hong Kong Morningside Group; provided hematological esoteric testing services in 18 provinces and cities nationwide; built a service network covering the whole province of Hubei. Wuhan Kindstar Medical Laboratory was rated by Science Times as one of the top ten independent medical laboratories in the field of laboratory medicine in China.

• By the end of 2007, Wuhan Kindstar and Beijing Hightrust have signed contracts with a total of 500 hospitals, and the rudimentary service network in Hubei province has been basically built.

• Provided medical testing services for all regions of Hubei Province.

• Provided medical testing services for some hospitals in Wuhan, invested in the establishment of Beijing Hightrust Medical Laboratory, and started esoteric testing services in Beijing.

• Trained personnel, cooperated with Wuhan Union Hospital of China, provided within-hospital esoteric testing services, and completed the preliminary survey of Wuhan’s medical testing market.

• Introduced internationally-advanced testing technologies, erected testing platforms, and established Wuhan Kindstar Medical Laboratory.